CTNM - CIK 0001855175
The table below shows Contineum Therapeutics, Inc.'s income statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | - | $0.00 | $50.00M |
| Cost of revenue | - | - | - |
| Gross profit | - | - | - |
| R&D | $51.52M | $38.42M | $27.60M |
| SG&A | $16.54M | $12.47M | $6.32M |
| Operating income | -$68.06M | -$50.89M | $16.08M |
| Income tax | $0.00 | $0.00 | $450.00K |
| Net income | -$59.98M |
Contineum Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2024. That is down 100.0% from $50.00M in fiscal 2023. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$42.26M |
| $22.72M |
| EPS (diluted) | -$2.17 | -$2.18 | $0.08 |